Loading...
Immune checkpoint inhibitors are now approved to combine with first-line chemotherapy in the treatment of metastatic esophagogastric cancer. Findings from previous trials led to approval of use of nivolumab or pembrolizumab as second-line treatment in metastatic squamous cancer of the esophagus.
Investigators now report the results of an industry-sponsored, international, randomized trial comparing chemotherapy with paclitaxel plus cisplatin plus either placebo or the anti–PD-1 agent sintilimab in patients with metastatic esophageal squamous cancer. Of 659 patients, the majority had combined positive score (CPS) >5% (74%) or >10% (58%) and a minority had undergone prior surgery (31%) or radiation therapy (19%).
The primary endpoint, overall s…